Smith & Nephew PLC Sponsored ADR Aktie News

Smith+Nephew (NYSE:SNN; LSE:SN), the global medical technology business, is pleased to announce exciting new data from Professor Amit Gefen and his research group published in the International Wound Journal,1 demonstrating the pressure injury prevention mechanism of action of ALLEVYN COMPLETE CARE Foam Dressing and its ability to absorb and dissipate friction and shear forces.

Completes the CORIOGRAPH Services portfolio which also includes solutions for knee and hip arthroplasty Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of its CORIOGRAPH Pre-Op Planning and Modeling Services for total shoulder arthroplasty, now available in the United States. This innovative software offers image-based planning capabilities tha...

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces new evidence and market updates that highlight the clinical performance of its REGENETEN Bioinductive Implant and support its further adoption. Substantial investment into research to expand access and indications have led to these important results designed to help surgeons treat more patients who suffer fr...

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of the CENTRIO Platelet-Rich-Plasma (PRP) System, a biodynamic hematogel derived from a patient's own platelets and plasma that, once applied, may assist the natural healing process by maintaining a moist wound environment.

Citi has reiterated its buy rating on Smith & Nephew PLC (LSE:SN) following recent meetings with the company's CEO and CFO. The bank highlights a constructive tone around the business despite the decision not to upgrade full-year guidance, citing global uncertainties and tough fourth-quarter comparisons.

Smith & Nephew's interim results confirm solid progress, with revenue up 5% and strong cash flow growth, supporting my continued 'buy' rating. Dividend growth has resumed after years of stagnation, and a $500m buyback signals management's confidence in cash generation, though yield remains modest. The company's recovery is gaining traction, even if ambitious margin targets remain unmet; momentu...

Citi has stuck with its ‘buy' call on Smith & Nephew PLC (LSE:SN) after the company delivered quarterly results that were, in Citi's words, “meaningfully better than expected”, and announced a $500mn share buyback that caught many by surprise. In its latest note, it highlighted that Smith & Nephew's organic growth for the second quarter came in “200–250 basis points above Visible Alpha consensu...

Smith & Nephew plc (NYSE:SNN ) Q2 2025 Earnings Conference Call August 5, 2025 3:30 AM ET Company Participants Deepak S. Nath - CEO & Director John Terence Rogers - CFO & Executive Director Conference Call Participants David James Adlington - JPMorgan Chase & Co, Research Division Dylan van Haaften - Stifel, Nicolaus & Company, Incorporated, Research Division Graham Doyle - UBS Investment Bank,...